Beth Hecht Sells 40,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 40,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Xeris Biopharma Stock Up 7.0 %

Shares of XERS opened at $5.81 on Friday. The stock has a 50 day moving average price of $3.88 and a 200 day moving average price of $3.41. The company has a market capitalization of $894.39 million, a price-to-earnings ratio of -12.91 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $5.92.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. NewEdge Advisors LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at approximately $34,000. R Squared Ltd purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $42,000. Cibc World Markets Corp purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $44,000. Raymond James Financial Inc. purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $45,000. Finally, Two Sigma Advisers LP purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $47,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Piper Sandler reissued a “neutral” rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum boosted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Leerink Partners boosted their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average price target of $5.92.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.